ClinicalTrials.Veeva

Menu

STOP Persistent AF PAS

M

Medtronic Cardiac Ablation Solutions

Status

Active, not recruiting

Conditions

Persistent Atrial Fibrillation

Treatments

Device: Arctic Front™ Cardiac Cryoablation Catheter System

Study type

Observational

Funder types

Industry

Identifiers

NCT05005949
STOP Persistent AF PAS

Details and patient eligibility

About

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

Full description

The STOP Persistent AF Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The PAS is a prospective, global, multicenter, observational trial. The purpose of the PAS is to describe long-term clinical performance and safety data in the Persistent AF population treated with Arctic Front™ and Freezor™ MAX Families of Cardiac Cryoablation Catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System). This PAS is a condition of the Pre-Market Approval order (P100010/S098) by the U.S. Food and Drug Administration. Up to 400 subjects will be enrolled to ensure 355 are treated. A minimum of 50% of patients will be enrolled and treated in the US. The follow-up duration for this post-approval study will be 36-months.

Enrollment

400 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject has been diagnosed with persistent AF.
  • Subject is ≥ 18 years of age or minimum age as required by local regulations.
  • Planned pulmonary vein isolation (PVI) procedure using commercially available Arctic Front™ Cardiac Cryoablation Catheter System.
  • Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements.

Exclusion criteria

  • Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL).
  • Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager.
  • Subject with exclusion criteria required by local law.

Trial contacts and locations

17

Loading...

Central trial contact

Mary Sauline; Jennifer Diouf

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems